RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) has received a key patent in the U.S. covering significant components of its novel, multi-needle dermal injection device.Read More
RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) reported statistically and clinically significant positive data from an interim analysis of its Phase I study evaluating RCS-01 for the treatment of aging and sun-damaged skin.Read More
RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP) announced the granting of two patents in Europe related to its multi-needle dermal injection technologies.Read More
Echelon Wealth Partners raised its price target for RepliCel Life Sciences (TSX-V:RP) to $2.15 from $1.50 after the company closed a unit offering that will add about $4.1-million in net cash to its balance sheet. The stock closed at $1.03 on Monday.
“The recapitalization provides funds to drive [RepliCel’s hair follicle-derived] non-bulbar dermal sheath cell platform forward with renewed vigor,” writes analyst Doug Loe, noting that he expects interim six-month data from a Phase 1/2 Achilles tendinosis/RCT-01 study by yearend.Read More